Biocon Biologics is a unique, fully integrated global biosimilars player, making a difference to over 5.7 million lives every year in more than 100 countries. With established capabilities in the development, manufacturing and commercialization of high-quality biosimilars, we want to enable equitable access to cost-effective, lifesaving biosimilars for patients worldwide. Biocon Biologics offers a comprehensive portfolio of 20 biosimilars — one of the widest and deepest in the industry.

Having completed the acquisition of Viatris’ global biosimilar business, we are leveraging end-to-end capabilities from lab to market, which not only widens our reach worldwide, but pushes us to greater heights in the biosimilars business.

Biocon Biologics has received investments from several marquee funds, which underscore the robustness of our business prospects. The investments validate our science, scale, scope, and strategy. They also reflect a high level of conviction in Biocon Biologics’ position as a global frontrunner in biosimilars, which leverages large-scale manufacturing capabilities to shift the access paradigm for these lifesaving therapies. The equity fundings enable us to expand our capabilities further, thus unlocking opportunities to create value for all our stakeholders.